Monday, December 18, 2017
 
 
News: Page (1) of 1 - 07/23/12 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Alzheimer's drug fails in 1 study, 2nd continues
Pfizer: Alzheimer's disease drug fails in 1 study, 2nd study in different patients continues
By The Associated Press

NEW YORK (AP) ¯¯¯ Drug maker Pfizer Inc. says a closely watched experimental Alzheimer's drug didn't slow the disease in one of two late-stage studies, but a second study in a different group of patients is continuing.

Pfizer, which is testing bapineuzumab (BAP'eh-new-ZOO'mab) with partner Johnson & Johnson, says the injected drug didn't slow mental or functional decline in patients with mild or moderate Alzheimer's disease. The study included patients who carry a gene called ApoE4, which gives people a higher risk of developing the memory-robbing disorder.

About half the population does not carry that gene, however, and Pfizer says a study of the drug in patients without the gene is continuing. Results of that study are expected to be announced later this summer.




Page: 1


 
 
 
 
 
 
 
 
 
 
 





Our Privacy Policy --- About The U.S. Daily News - Contact Us - Advertise With Us - Privacy Guidelines